PDCD1 and neoplasm: Furthermore, using a suboptimal administration scheme of anti-PD-1 in which the tumor burden is not reduced by monotherapy, we provide evidence that coadministration of SAM is sufficient to potentialize the effect of anti-PD-1 and induce a strong antitumor immune response.